

MITOCHONDRIAL AND INHERITED METABOLIC DISEASES TASK FORCE WITH CRITICAL PATH INSTITUTE (C-PATH)

About C-Path



press release

C-Path's Rare Diseases Cures Accelerator – Data Analytics Platform (RDCA-DAP®) is an FDA-funded initiative establishing a centralized and standardized infrastructure. This platform facilitates the sharing of crucial data across rare diseases, enabling integration and standardization of diverse data types, e.g., registry, trials, etc.

Mission

Standardizing and integrating mitochondrial and inherited metabolic diseases data into the RDCA-DAP®.

Optimizing clinical trial design and endpoints.

Enhancing communication and collaboration among stakeholders, and the medical and research communities at large, all aimed at improving the lives of those affected by these diseases.

Why share data?

By participating or sharing data with C-Path your data is entrusted to a **neutral entity** with expertise in **data governance**, sharing, proper **data aggregation and analytics**, and **working with regulatory bodies**.

Data contributors decide how their data is shared and used.

All of this together has the **maximum chance** of benefiting as many **people living with mitochondrial and metabolic diseases** as possible.

Members

Astellas Pharma Inc.
Azer Consulting, LLC
Barth Syndrome Foundation
Cure ARS
Cure LBSL Foundation
Cure Mito Foundation
Critical Path Institute
Global Genes: Rare-X Platform
Hope for PDCD
LHON Collective
Lily Foundation

Mepan Foundation
MitoAction
MitoCanada
Mitochondria World
Midwestern Washington
University
National Institutes of Health
Sanford Research
The Champ Foundation
Newcastle upon Tyne
St. Louis University